The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer who are at high risk of disease recurrence (D-CARE): An international, randomized, double-blind, placebo-controlled phase III clinical trial.
Paul Edward Goss
Honoraria - Novartis; Pfizer
Carlos H. Barrios
No relevant relationships to disclose
Richard Bell
Consultant or Advisory Role - Amgen
Research Funding - Amgen
Dianne M Finkelstein
No relevant relationships to disclose
Hiroji Iwata
No relevant relationships to disclose
Miguel Martin
Consultant or Advisory Role - Amgen; Genomic Health; Roche/Genentech
Ada H. Braun
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Chunlei Ke
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Tapan Maniar
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Robert Edward Coleman
Consultant or Advisory Role - Novartis
Expert Testimony - Novartis